GRI

GRI Bio Inc develops immune-modulating therapies targeting NKT cells for inflammatory and fibrotic diseases. The company focuses on addressing NKT cell dysfunction, which plays a role in conditions like pulmonary fibrosis and autoimmune disorders, aiming to restore immune balance.

GRI Bio's stock has seen significant volatility, trading between $1.98 and $80.08 over the past year. As of June 2026, shares rose 7.43% to $2.17 amid broader biotech sector gains, reflecting the high-risk, high-reward nature of early-stage biotech investments.

GRI Bio reported no revenue in its most recent annual and trailing twelve-month periods, with net losses of $11.96 million annually and $10.91 million TTM. The company's cash position stood at $6.97 per share as of the last quarterly report.

GRI Bio's customer segments include biopharmaceutical companies seeking partnerships, academic medical centers for clinical research, specialty pharmacies serving autoimmune and pulmonary patients, and hospital systems with advanced treatment programs.

GRI Bio's strengths include its focus on NKT cell biology, an underexplored area with broad therapeutic potential, a strong intellectual property position in immune modulation, and public listing providing access to capital markets for funding development.

GRI Bio faces risks including no revenue generation with significant R&D expenses, a high cash burn rate requiring future financing, and clinical trial risks inherent in early-stage biotech development, which could impact its financial stability and stock performance.